Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Life Technologies Announces Second Quarter 2013 Results

Published: Thursday, August 01, 2013
Last Updated: Thursday, August 01, 2013
Bookmark and Share
Revenue increased 1% excluding impact of currency.

Life Technologies Corporation announced results for its second quarter ended June 30, 2013.  Revenue for the second quarter was $944 million, a decrease of 1 percent over the $950 million reported for the second quarter of 2012.  Excluding the impact of currency, revenue growth for the quarter was 1 percent compared to the same period of the prior year.

"We are pleased to report results that reflect significant growth in Ion Torrent, strength in Applied Sciences and continued stable performance in Research Consumables," said Gregory T. Lucier, chairman and chief executive officer of Life Technologies. "During the quarter, we added to our innovation pipeline, launching novel tools for stem cell research, digital qPCR and Ion Torrent. We continued to expand into growth and emerging markets by acquiring our instrument distributor in South Korea, and by entering into strategic relationships that apply our technologies to therapeutic areas like oncology."

Lucier continued, "We are actively working with Thermo Fisher to consummate our previously announced transaction. We recently filed our definitive proxy and will be hosting our special meeting of stockholders on August 21, 2013.  Both companies remain excited about creating the unrivaled leader in life sciences that will continue to accelerate innovation and better meet the needs of our customers."

Life Technologies reported results compared to the quarter ended June 30, 2012.  Results are non-GAAP unless indicated otherwise. A full reconciliation of non-GAAP to GAAP measures can be found in the tables of today's press release.

Analysis of Second Quarter 2013 Results

•    Second quarter revenue decreased by 1 percent over the prior year, representing an increase of approximately 1 percent excluding the impact of currency.  Revenue growth for the quarter was driven by a significant increase in sales from Ion Torrent, an increase in the Research Consumables business and higher royalties including licensing agreements, partially offset by lower CE for research, SOLiD and Bioproduction sales.
•    Gross margin in the second quarter was 65.9 percent, an increase of approximately 50 basis points over the same period of the prior year that was driven by manufacturing productivity, revenue from licensing agreements and higher realized price, partially offset by product mix with the continued increase in Ion Torrent instrument sales.
•    Operating margin was 27.4 percent in the second quarter, approximately 120 basis points lower than in the same period of the prior year. Operating margin was primarily impacted by increased expenses related to acquisitions and planned investments in Ion Torrent and molecular diagnostics.
•    The Company's tax rate was 25.0 percent for the second quarter.  The rate was lower than in the second quarter of last year due to the reinstatement of the US research tax credit, greater earnings in countries with lower tax rates and the settlement of income tax audits.
•    Second quarter EPS increased 2 percent to $0.98.
•    Diluted weighted shares outstanding were 175.6 million in the second quarter, a decrease of 5.7 million shares over the prior year.  The decrease was a result of the share repurchase program, partially offset by shares issued for employee stock plans.
•    Cash flow from operating activities for the second quarter was $219 million. Second quarter capital expenditures were $23 million, resulting in free cash flow of $196 million.  The company ended the quarter with $290 million in cash and short-term investments.

Business Group and Regional Highlights

•    Research Consumables revenue was $405 million in the second quarter, an increase of 1 percent compared to the prior year.  Excluding the impact of currency, revenue for the business group increased 2 percent primarily due to strong sales from the Company's fluorescent imaging, stem cell and sample prep products.
•    Genetic Analysis revenue was $341 million in the second quarter, a decrease of 4 percent over the same period last year. Excluding the impact of currency, revenue decreased 2 percent. Results for the quarter were primarily driven by an increase in Ion Torrent sales, offset by lower CE research sales, primarily due to large customer orders in the second quarter of the prior year and an expected decline in SOLiD.
•    Applied Sciences revenue was $198 million in the second quarter, an increase of 2 percent over the prior year.  Excluding the impact of currency, revenue increased 4 percent primarily as a result of licensing agreements, partially offset by a decline in the Company's Bioproduction business due to the timing of customer orders.
•    Regional revenue growth rates excluding currency for the second quarter, compared to the same quarter of the prior year, were as follows: the Americas declined 1 percent, Europe was flat, Asia Pacific grew 4 percent, and Japan grew 6 percent.

Outlook

Given the announcement in April that Life Technologies and Thermo Fisher have entered into a definitive merger agreement under which Thermo Fisher will acquire all of the outstanding shares of Life Technologies for $76.00 per share in cash, the Company is no longer providing quarterly guidance.  The Company will continue to provide commentary regarding the impact that fluctuations in currency rates could have on results.

Based on June 30, 2013 rates, currency is expected to have a negative impact of approximately $75 million on revenue and $0.17 on non-GAAP EPS for the full year.  This compares to a negative impact of $62 million on revenue and $0.15 on non-GAAP EPS for the full year at March 31, 2013 rates.

Conference Calls

In light of the announced transaction with Thermo Fisher, the Company will no longer hold conference calls for its quarterly and annual earnings. The transaction, which is expected to close early in 2014, is subject to a Life stockholder vote and customary closing conditions, including regulatory approvals.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

FBI Approves Life Technologies' Forensics Kit
Ability to upload forensic samples to National DNA Index System using GlobalFiler DNA chemistry enables faster, more powerful data comparisons to solve crimes in the U.S. and globally.
Tuesday, June 24, 2014
Distribution Agreement to Offer GlobalFiler Express Chemistry
Life Technologies today announced it has signed an agreement giving IntegenX Inc. the rights to distribute its GlobalFiler Express chemistry on IntegenX’s RapidHIT™ platform.
Wednesday, February 26, 2014
Life Technologies' Ion AmpliSeq™ Exome Program Adds 12 New Members
With more than 30 members the program is the largest network of next generation-based exome sequencing providers in the world.
Friday, December 20, 2013
Life Tech's Food Pathogen Detection Methods Approved by Australian Government
MicroSEQ Real-Time PCR workflows approved as method for testing Australian export meat and meat products.
Tuesday, December 17, 2013
KACST Partners with Life Tech in The Saudi Human Genome Program
Program aims to analyze 100,000 human genomes to identify the causes of disease in the population of the Kingdom of Saudi Arabia and the Arab world.
Monday, December 09, 2013
Life Technologies Awards Digital PCR Innovation Grants to Five Research Labs
The five Innovation Grant recipients in the Digital PCR Applications Grant Program was announced during the ASHG conference in Boston.
Thursday, October 24, 2013
BGI Partners with Life Technologies
World's largest genome center to purchase 50 Ion Proton™ Sequencers from Life Technologies.
Tuesday, October 22, 2013
Life Technologies Extends Partnership with DNAVEC
R&D collaborative agreement aims to further develop Sendai virus-based tools for basic and translational research.
Monday, October 21, 2013
Life Tech's Forensic Kit Approved by FBI
Life Technologies GlobalFiler™ Express Kit has been approved by the FBI for use by laboratories generating DNA profiles for inclusion in the National DNA Index System CODIS Database.
Friday, October 11, 2013
Life Technologies Expand Ion AmpliSeq™ Exome Certified Service Provider Program
Due to increased demand the program is expanding to include eleven new members.
Wednesday, October 09, 2013
TriCore Reference Laboratories Named First NGS Center of Excellence by Life Technologies
Collaborative partnership designed to accelerate clinical research in the Southwest using advanced NGS oncology panels.
Thursday, September 19, 2013
Thermo Acquisition Approved by Life Technologies Stockholders
Company announced that its stockholders voted to adopt the previously announced merger agreement.
Thursday, August 22, 2013
Life Technologies Enters into an Exclusive License and Supply Agreement for Dynabead
Life Technologies has signed a long-term supply and exclusive licensing agreement with Novartis for immunotherapeutics involving T cells modified to express chimeric antigen receptors for the treatment of cancer.
Thursday, August 01, 2013
Life Technologies Opens State-of-the-Art DNA Forensics Laboratory in India
The new Life Forensics Laboratory will provide much needed high-throughput DNA profiling services in India to help accelerate the sampling process, while saving time and money.
Thursday, August 01, 2013
Life Technologies Signs Five-Year Agreement with the FDA
The agreement aims to accelerate and advance food safety testing of E. coli and Salmonella, two foodborne contaminants commonly associated with outbreaks and/or recalls.
Tuesday, July 30, 2013
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!